Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran.
Iranians
Metabolic-associated fatty liver disease
Non-alcoholic fatty liver disease
Risk factors
Journal
Gastroenterology and hepatology from bed to bench
ISSN: 2008-2258
Titre abrégé: Gastroenterol Hepatol Bed Bench
Pays: Iran
ID NLM: 101525875
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
06
2021
accepted:
20
08
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
ppublish
Résumé
This study aimed to identify the risk factors of metabolic (dysfunction)-associated fatty liver disease (MAFLD) among adults in northeastern Iran. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and hepatic manifestation of metabolic syndrome that threatens global public health. Recently, MAFLD has been proposed as a new terminology updated from NAFLD and diagnosed based on modified criteria. A nested case-control study was performed on the participants of the first phase of the Persian Sabzevar Cohort Study (PSCS), a survey that was conducted in northeastern Iran and enrolled 4,242 participants aged 35-70 years. In total, 968 MAFLD cases and 964 controls adjusted for age and sex were recruited. Data including demographic, lifestyle, anthropometric, biochemical, sleep pattern, and dietary intake information was collected. The mean (SD [standard deviation]) age of participants was 49.2 (8.8) years, and 39.9% of the participants were males. The prevalence of MAFLD was 22.8% (95% CI [confidence interval] 19.2 - 26.3%). Increased body mass index (BMI) (OR [odds ratios] 5.51, 95% CI 2.73 - 11.10), waist circumference (WC) (OR 1.85, 95% CI 1.44 - 2.38), blood concentrations of triglycerides (TG) (OR 1.10, 95% CI 1.06 - 1.15), total cholesterol (TC) (OR 1.02, 95% CI 1.003 - 1.04), and alanine aminotransferase (AST) (OR 1.10, 95% CI 1.05 - 1.16) were significantly associated with an increased risk of the MAFLD ( In this study, it was found that MAFLD was best predicted by BMI, WC, and serum levels of TG, total cholesterol, and AST. Sleeping ≤ 5hrs/day compared to ≥ 7hrs/day was associated with an increased risk of MAFLD.
Sections du résumé
AIM
OBJECTIVE
This study aimed to identify the risk factors of metabolic (dysfunction)-associated fatty liver disease (MAFLD) among adults in northeastern Iran.
BACKGROUND
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and hepatic manifestation of metabolic syndrome that threatens global public health. Recently, MAFLD has been proposed as a new terminology updated from NAFLD and diagnosed based on modified criteria.
METHODS
METHODS
A nested case-control study was performed on the participants of the first phase of the Persian Sabzevar Cohort Study (PSCS), a survey that was conducted in northeastern Iran and enrolled 4,242 participants aged 35-70 years. In total, 968 MAFLD cases and 964 controls adjusted for age and sex were recruited. Data including demographic, lifestyle, anthropometric, biochemical, sleep pattern, and dietary intake information was collected.
RESULTS
RESULTS
The mean (SD [standard deviation]) age of participants was 49.2 (8.8) years, and 39.9% of the participants were males. The prevalence of MAFLD was 22.8% (95% CI [confidence interval] 19.2 - 26.3%). Increased body mass index (BMI) (OR [odds ratios] 5.51, 95% CI 2.73 - 11.10), waist circumference (WC) (OR 1.85, 95% CI 1.44 - 2.38), blood concentrations of triglycerides (TG) (OR 1.10, 95% CI 1.06 - 1.15), total cholesterol (TC) (OR 1.02, 95% CI 1.003 - 1.04), and alanine aminotransferase (AST) (OR 1.10, 95% CI 1.05 - 1.16) were significantly associated with an increased risk of the MAFLD (
CONCLUSION
CONCLUSIONS
In this study, it was found that MAFLD was best predicted by BMI, WC, and serum levels of TG, total cholesterol, and AST. Sleeping ≤ 5hrs/day compared to ≥ 7hrs/day was associated with an increased risk of MAFLD.
Types de publication
Journal Article
Langues
eng
Pagination
S102-S111Informations de copyright
©2021 RIGLD, Research Institute for Gastroenterology and Liver Diseases.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Lipids Health Dis. 2017 Oct 16;16(1):203
pubmed: 29037210
Gut. 2020 Sep;69(9):1691-1705
pubmed: 32321858
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Diabetes Metab Syndr Obes. 2021 May 06;14:2029-2039
pubmed: 33986604
Best Pract Res Clin Endocrinol Metab. 2010 Oct;24(5):687-702
pubmed: 21112019
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Atherosclerosis. 2014 Jan;232(1):99-109
pubmed: 24401223
Br J Nutr. 2021 Aug 23;:1-6
pubmed: 34420544
World J Gastroenterol. 2014 Jul 14;20(26):8407-15
pubmed: 25024598
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10
pubmed: 33348045
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
J Gastroenterol Hepatol. 2016 May;31(5):936-44
pubmed: 26667191
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
ARYA Atheroscler. 2015 Mar;11(2):139-46
pubmed: 26405443
J Hepatol. 2020 Apr;72(4):785-801
pubmed: 32059982
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Adv Ther. 2019 Jul;36(7):1574-1594
pubmed: 31065991
Chin Med J (Engl). 2020 Oct 5;133(19):2271-2273
pubmed: 32701591
Arch Iran Med. 2010 Sep;13(5):426-8
pubmed: 20804311
J Gastrointestin Liver Dis. 2019 Mar;28(1):73-81
pubmed: 30851175
Metabolism. 2016 Aug;65(8):1109-23
pubmed: 27237577
Am J Epidemiol. 2018 Apr 1;187(4):647-655
pubmed: 29145581
J Diabetes Metab Disord. 2014 Mar 06;13(1):44
pubmed: 24602504
Liver Int. 2016 Mar;36(3):427-33
pubmed: 26346413
Dig Liver Dis. 2015 Mar;47(3):181-90
pubmed: 25739820
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Metabolism. 2018 Jul;84:56-66
pubmed: 29510179
PLoS Med. 2019 Feb 4;16(2):e1002741
pubmed: 30716101
J Gastroenterol Hepatol. 2020 Dec;35(12):2041-2050
pubmed: 32573017
Sleep Med. 2019 May;57:144-150
pubmed: 30991275
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90
pubmed: 24042449
Curr Pharm Des. 2020;26(10):1079-1092
pubmed: 32003662
Sleep. 2009 Feb;32(2):200-4
pubmed: 19238807
Clin Gastroenterol Hepatol. 2022 Mar;20(3):e573-e582
pubmed: 33618024
Nat Rev Endocrinol. 2017 Sep;13(9):509-520
pubmed: 28621339
J Steroid Biochem Mol Biol. 2020 Oct;203:105737
pubmed: 32818561
Nutr Metab (Lond). 2021 Sep 8;18(1):82
pubmed: 34496912
Health Policy Plan. 2006 Nov;21(6):459-68
pubmed: 17030551
Diabetol Metab Syndr. 2015 Mar 24;7:25
pubmed: 25834642
Mol Metab. 2020 Dec;42:101092
pubmed: 33010471